Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Вакцинация в ревматологии: современность и перспективы

https://doi.org/10.33667/2078-5631-2019-2-37(412)-44-49

Полный текст:

Аннотация

В ревматологии за последнее время значимость коморбидных инфекций существенно увеличилась, особенно в связи с внедрением в клиническую практику генно-инженерных биологических препаратов. Одним из путей решения указанной проблемы является изучение и активное применение различных вакцин. В настоящем обзоре представлен обновленный вариант рекомендаций по вакцинации взрослых больных с аутоиммунными воспалительными ревматическими заболеваниями, предложенный в 2019 году экспертами Европейской антиревматической лиги (EULAR). Рассмотрены вопросы, касающиеся применения вакцин против гриппа, инфекций, обусловленных пневмококками, вирусами гепатита В, герпеса и папилломы человека, у ревматологических больных. Обозначены основные направления будущих исследований по рассматриваемой проблеме.

Об авторах

Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия

Лаборатория изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

д. м. н., зав. лабораторией

г. Москва



Г. М. Тарасова
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия

Лаборатория изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

к. м. н., с. н. с.

г. Москва



Д. В. Буханова
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия

Лаборатория изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

аспирант

г. Москва



Н. В. Муравьева
ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»
Россия

Лаборатория изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

к. м. н., н. с.

г. Москва



Список литературы

1. Wolfe F., Mitchell D. M., Sibley J. T. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37 (4): 481–494.

2. Edwards C. J., Lian T. Y., Badsha H., et al. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 2003; 12 (9): 672–676.

3. Tyndall A.J, Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69 (10): 1809–15. DOI: 10.1136/ard.2009.114264.

4. Решетняк Т. М. Антифосфолипидный синдром: клиника, диагностика и вопросы патогенеза. Автореф. дисс… докт. мед. наук. М.,1999. 57 с.

5. Asherson R.A, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome — molecular mimicry? J Rheumatol. 2000; 27 (1): 12–14.

6. Perry L. M., Winthrop K. L., Curtis J. R. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014; 16 (8): 431. DOI: 10.1007/s11926–014–0431-x.

7. Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016; 28 (3): 330–6. DOI: 10.1097/BOR.0000000000000281.

8. Friedman M. A., Winthrop K. L. Vaccines and Disease–Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. Rheum Dis Clin North Am. 2017; 43 (1): 1–13. DOI: 10.1016/j.rdc.2016.09.003.

9. Furer V, Rondaan C, Heijstek MW et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. DOI: 10.1136/annrheumdis-2019–215882.

10. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza–related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012; 13: 158. DOI: 10.1186/1471–2474–13–158.

11. Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012; 41 (5): 359–65. DOI: 10.3109/03009742.2012.670729.

12. Bello SL, Serafino L, Bonali C, et al. Incidence of influenza–like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012; 64 (5): 299–306. DOI: 10.4081/reumatismo.2012.299.

13. Mohammad AJ, Segelmark M, Smith R, et al. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. J Rheumatol. 2017; 44 (10): 1468–1475. DOI: 10.3899/jrheum.160909.

14. Kapetanovic M. C., Kristensen L. E., Saxne T., et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N 1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014; 16 (1): R 2. DOI: 10.1186/ar4427.

15. Hak E, Nordin J, Wei F, et al. Influence of high–risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002; 35 (4): 370–7.

16. Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016; 6: 37817. DOI: 10.1038/srep37817.

17. Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 2013; 42 (6): 445–50. DOI: 10.3109/03009742.2013.788733.

18. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010; 62 (1): 75–81. DOI: 10.1002/art.25033.

19. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011; 29 (8): 1643–8. DOI: 10.1016/j.vaccine.2010.12.072.

20. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018; 77 (6): 898–904. DOI: 10.1136/annrheumdis-2018–213222.

21. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease modifying antirheumatic drugs on antibody responses to the AS 03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63: 1486–96. DOI: 10.1002/art.30325.

22. Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol. 2014; 177 (1): 287–94. DOI: 10.1111/cei.12292.

23. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N 1 vaccination in immunemediated disease — a prospectively controlled vaccination study. Rheumatology 2012; 51: 695–700. DOI: 10.1093/rheumatology/ker389.

24. Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N 1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014; 16 (1): R 2. DOI: 10.1186/ar4427.

25. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N 1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken). 2011; 63 (7): 1062–7. DOI: 10.1002/acr.20465.

26. Miossi R, Fuller R, Moraes JC, et al. Immunogenicity of influenza H1N 1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics (Sao Paulo). 2013; 68 (2): 129–34.

27. Shinjo S. K., de Moraes J. C., Levy–Neto M., et al. Pandemic unadjuvanted influenza A (H1N 1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease. Vaccine. 2012; 31 (1): 202–6.

28. Koivuniemi R., Leirisalo-Repo M., Suomalainen R., et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand. J. Rheumatol., 2006, 35, 273–6. DOI: 10.1080/03009740600556258.

29. Nossent J., Cices N., Kiss E. Marchesoni A., Nassonova V., Mosca M. et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus, 2007, 16, 309–17.

30. Narata R., Wangkaew S., Kasitanon N., Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast. Asian. J. Trop. Med. Public. Health, 2007, 38, 3, 528–36.

31. Kaine J. L., Kivitz A. J., Birbara C., Luo A. Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007; 34 (2): 272–9.

32. Kapetanovic M. C., Saxne T., Sjöholm A., et al.. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology. 2006; 45 (1): 106–11.

33. Bingham C. O. 3rd, Rizzo W., Kivitz A., et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015; 74 (5): 818–22. doi: 10.1136/annrheumdis-2013–204427.

34. Kapetanovic M. C., Kristensen L. E., Saxne T., et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N 1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014; 16 (1): R 2. DOI: 10.1186/ar4427.

35. Bingham C. O. 3rd, Looney R. J., Deodhar A. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010; 62 (1): 64–74.

36. Crnkic Kapetanovic M., Saxne T., Jönsson G., et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013; 15 (5): R 171.

37. Наумцева М. С., Белов Б. С., Александрова Е. Н., и др. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология. 2016; 54 (6): 674–680.

38. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816–9.

39. Чучалин А. Г., Брико Н. И., Авдеев С. Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019; 29 (1): 19–34. DOI: 10.18093/0869–0189–2019–29–1–19–34.

40. Kapetanovich M., Nagel J., Nordström I., et al.. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine 2017 35 (6): 903–908. DOI: 10.1016/j.vaccine.2016.12.068.

41. Salinas G. F., De Rycke L., Barendregt B., et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013; 72: 1037–43. DOI: 10.1136/annrheum-dis-2011–201270.

42. Grabar S., Groh M., Bahuaud M., et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017; 35 (37): 4877–4885. DOI: 10.1016/j.vaccine.2017.07.094.

43. Zhao J, Qiu M, Li M, et al. Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China. Rheumatol Int 2010; 30: 1565–70.

44. Chiu Y-M, Lai M-S, Chan KA. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. PLoS One 2018; 13: e0196210. DOI: 10.1371/journal.pone.0196210.

45. Curtis J.R, Yang S., Chen L., et al. Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination. Ann Rheum Dis 2014; 73: Suppl 2: 452.

46. Che H., Lukas C., Morel J., Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014; 81 (3): 215–21.

47. Atzeni F, Talotta R, Nucera V, et al.Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018 Nov; 14 (11): 945–956. DOI: 10.1080/1744666X.2018.1504678.

48. Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD 4+ T cell immune response in vitro inlymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 Nov 1; 58 (11): 2051–2060. DOI: 10.1093/rheumatology/kez175.

49. Zhang J., Xie F., Delzell E., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012; 308 (1): 43–9. DOI: 10.1001/jama.2012.7304.

50. Klumb E. M., Pinto A. C., Jesus G.R,, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010; 19 (13): 1485–91. DOI: 10.1177/0961203310372952.

51. Lyrio L. D., Grassi M. F., Santana I. U. et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013; 33 (2): 335–40. DOI: 10.1007/s00296–012–2426–0.

52. Mok C. C., Ho L. Y., Fong L. S., To C. H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013; 72 (5): 659–64. DOI: 10.1136/annrheumdis-2012–201393.

53. Dhar J.P, Essenmacher L., Dhar R., et al. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017; 35 (20): 2642–2646. DOI: 10.1016/j.vaccine.2017.04.001.


Для цитирования:


Белов Б.С., Тарасова Г.М., Буханова Д.В., Муравьева Н.В. Вакцинация в ревматологии: современность и перспективы. Медицинский алфавит. 2019;2(37):44-49. https://doi.org/10.33667/2078-5631-2019-2-37(412)-44-49

For citation:


Belov B.S., Tarasova G.M., Bukhanova D.V., Muravyeva N.V. Vaccination in rheumatology: present and prospects. Medical alphabet. 2019;2(37):44-49. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-37(412)-44-49

Просмотров: 84


ISSN 2078-5631 (Print)